Buy Rating Reaffirmed for Airsculpt Technologies Amid Strategic Growth Initiatives

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Airsculpt Technologies, Inc. (AIRS – Research Report), retaining the price target of $8.25.

Whit Mayo has given his Buy rating due to a combination of factors concerning Airsculpt Technologies, Inc.’s strategic positioning and market initiatives. Despite a weaker first quarter, Mayo remains confident in the company’s ability to meet its 2024 guidance. This confidence stems from the company’s proactive measures in customer acquisition and awareness campaigns, which are expected to boost lead traffic. Furthermore, new center openings are progressing ahead of schedule, reinforcing the potential for revenue growth and market penetration.

While acknowledging the challenges posed by a significant seasonal earnings ramp required in the remaining quarters of the year, Mayo believes that Airsculpt Technologies is on a solid path to recovery. The reiteration of the 2024 guidance suggests a strong second half of the year, backed by strategic initiatives aimed at overcoming current macro-economic and industry-specific headwinds. The company’s modest increase in revenue per case also indicates an ability to maintain pricing power, which is a positive sign in a competitive aesthetic and high-end retail market.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Airsculpt Technologies, Inc. (AIRS) Company Description:

AirSculpt Technologies Inc is a provider of body contouring procedures delivering a premium consumer experience. It provides a custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. Its mission is to generate the best results for patients.